Therapeutic analysis of cannabidiol for Alzheimer treatment
DOI:
https://doi.org/10.33448/rsd-v13i2.45006Keywords:
Alzheimer disease; Therapeutic; Cannabidiol; Treatment.Abstract
Objective: To analyze therapeutic evidence regarding the potential antioxidant, anti-inflammatory and neuroprotective effects of cannabidiol (CBD) and its effectiveness for the treatment of Alzheimer's Disease (AD). Methodology: Data collection, in the Virtual Health Library, targeting the primary databases Medical Literature Analysis and Retrieval System Online (Medline) and Latin American and Caribbean Literature in Health Sciences (Lilacs) to answer the research question: is the therapeutic use of cannabidiol effective in improving the treatment of patients with Alzheimer's Disease? Results: 14 articles were selected, after analyzing the inclusion and exclusion criteria, all after 2017, with the largest number concentrating on systematic literature review or meta-analysis. Conclusion: Cannabidiol has clear potential to reduce the symptoms of AD given its action on the Central Nervous System. Therefore, its therapeutic use in the treatment of AD emerges as a promising field of investigation, highlighting its relevance as a safe and effective treatment option. Therefore, an in-depth understanding of the antioxidant, anti-inflammatory and neuroprotective properties of CBD is necessary, not only for a better clinical definition of AD, but also for a series of neurological diseases that still have undefined treatments. The potential of CBD, therefore, represents a valuable alternative in the context of neurology, offering significant perspectives for the treatment of neurodegenerative conditions.
References
Bitencourt, E. M., Kuerten, C. M. X., Budny, J., & Tuo, T. (2018). Alzheimer's Disease: physiopathological aspects, quality of life, therapeutic strategies of physiotherapy and biomedicine. Revista Inova Saúde, 8(2), 2317-2460. https://doi.org/10.18616/inova.v8i2.3573
Bittes, Y. P., Ribeiro, L. B., Anselmo, G. S. Dantas, T. C. L., Ferreira, M. V. R., Neves, W. C., Barbosa, J. S. P., Silva, D. F. (2021). Use of cannabinoids in the treatment of persons with Alzheimer. Revisa (online) 10 (2), 887-899. https://pesquisa.bvsalud.org/portal/resource/pt/biblio-1354211
Borghi, A. C., Sassá, A. H., Matos, P. C. B., Decesaro, M. N., & Marcon, S. S. (2011) Quality of life of elders with Alzheimer's disease and of their caregiver. Revista Gaúcha de Enfermagem, 32(4), 1983-1447. https://doi.org/10.1590/S1983-14472011000400016
Camargo Filho, F. M. A., Romanini, A. P., Pyrich, B. C. et al. (2019) Canabinoides como uma nova opção terapêutica nas doenças de Parkinson e de Alzheimer: uma revisão de literatura. Revista Brasileira de Neurologia, 55(2), 17–32. https://fi-admin.bvsalud.org/document/view/nsxb2
Cooray, R., Gupta, V., & Suphioglu, C. (2020). Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson's and Alzheimer's Diseases: a Review. Molecular neurobiology, 57(11), 4878–4890. https://doi.org/10.1007/s12035-020-02054-6
Crippa, J. A. S., Guimarães, F. S., Zuardi, A. W., & Hallak, J. E. C. (2023). Dr. Raphael Mechoulam, cannabis and cannabinoids research pioneer and his legacy for Brazilian pharmacology. Revista brasileira de psiquiatria (Sao Paulo, Brasil: 1999), 45(3), 201–202. https://doi.org/10.47626/1516-4446-2023-0047
Dash, R., Ali, M. C., Jahan, I., Munni, Y. A., Mitra, S., Hannan, M. A., Timalsina, B., Oktaviani, D. F., Choi, H. J., & Moon, I. S. (2021). Emerging potential of cannabidiol in reversing proteinopathies. Ageing research reviews, 65, 101209. https://doi.org/10.1016/j.arr.2020.101209
Elsaid, S., Kloiber, S., & Le Foll, B. (2019). Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings. Progress in molecular biology and translational science, 167, 25–75. https://doi.org/10.1016/bs.pmbts.2019.06.005
Flores, E. L., & Zamin, L. L. (2017). Potencial neuroprotetor, antioxidante e anti-inflamatório do Canabidiol: relevância e perspectivas para o tratamento de doenças neurodegenerativas. Revista De Ciências Médicas E Biológicas, 16(2), 224–229. https://doi.org/10.9771/cmbio.v16i2.20568
Fonseca, B.M.; Costa, M. A.; Almada, M. et al. (2013). O Sistema Endocanabinóide – uma perspetiva terapêutica. Acta Farmacêutica Portuguesa, v. 2, n. 2, p. 37–44. https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/5
Fonseca, C., Ettcheto, M., Bicker, J., Fernandes, M. J., Falcão, A., Camins, A., & Fortuna, A. (2023). Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy? Ageing research reviews, 90, 101998. https://doi.org/10.1016/j.arr.2023.101998
Garcia, A. K. A., Fonseca, L. F., Aroni, P., & Galvão, C. M. (2016). Strategies for thirst relief: integrative literature review. Revista Brasileira de Enfermagem - REBEn, 69(6), 1215-1222. https://doi.org/10.1590/0034-7167-2016-0317
Jiang, X., Zhang, Z., Zuo, J., Wu, C., Zha, L., Xu, Y., Wang, S., Shi, J., Liu, X. H., Zhang, J., & Tang, W. (2021). Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease. European journal of medicinal chemistry, 223, 113735. https://doi.org/10.1016/j.ejmech.2021.113735
Jørgensen, J. T., Hansen, J., Westendorp, R. G. J., Nabe-Nielsen, K., Stayner, L. T., Simonsen, M. K., & Andersen, Z. J. (2020). Shift work and incidence of dementia: A Danish Nurse Cohort study. Alzheimer's & dementia: the journal of the Alzheimer's Association, 16(9), 1268–1279. https://doi.org/10.1002/alz.12126
Kim, J., Choi, P., Park, Y. T., Kim, T., Ham, J., & Kim, J. C. (2023). The Cannabinoids, CBDA and THCA, Rescue Memory Deficits and Reduce Amyloid-Beta and Tau Pathology in an Alzheimer's Disease-like Mouse Model. International journal of molecular sciences, 24(7), 6827. https://doi.org/10.3390/ijms24076827
Kozela, E., Juknat, A., & Vogel, Z. (2017). Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid. International journal of molecular sciences, 18(8), 1669. https://doi.org/10.3390/ijms18081669
Leszko, M., & Meenrajan, S. (2021). Attitudes, beliefs, and changing trends of cannabidiol (CBD) oil use among caregivers of individuals with Alzheimer's disease. Complementary therapies in medicine, 57, 102660. https://doi.org/10.1016/j.ctim.2021.102660
Li, H., Liu, Y., Tian, D., Tian, L., Ju, X., Qi, L., Wang, Y., & Liang, C. (2020). Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer's disease. European journal of medicinal chemistry, 192, 112163. https://doi.org/10.1016/j.ejmech.2020.112163
Mannucci, C., Navarra, M., Calapai, F., Spagnolo, E. V., Busardò, F. P., Cas, R. D., Ippolito, F. M., & Calapai, G. (2017). Neurological Aspects of Medical Use of Cannabidiol. CNS & neurological disorders drug targets, 16(5), 541–553. https://doi.org/10.2174/1871527316666170413114210
Melnyk B. M., & Fineout-Overholt, E. (2005) Making the case for evidence-based practice. Evidence-based practice in nursing & healthcare. A guide to best practice. Lippincot Williams & Wilkins, Philadelphia, p.3-24.
Organização das Nações Unidas (2022). Demência pode afetar 78 milhões de pessoas até 2030, diz OMS. ONU News. Perspectiva Global Reportagens Humanas. https://news.un.org/pt/story/2022/10/1804302
Ownby, R. L., Crocco, E., Acevedo, A., John, V., & Loewenstein, D. (2006). Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Archives of general psychiatry, 63(5), 530–538. https://doi.org/10.1001/archpsyc.63.5.530
Silva, S., Bicker, J., Falcão, A., & Fortuna, A. (2021). Antidepressants and Circadian Rhythm: Exploring Their Bidirectional Interaction for the Treatment of Depression. Pharmaceutics, 13(11), 1975. https://doi.org/10.3390/pharmaceutics13111975
Souza, M. T., Silva, M. D., & Carvalho, R. (2010). Revisão integrativa: o que é e como fazer Integrative review: what is it? How to do it? Einstein, 8(1), 102–108. https://doi.org/10.1590/S1679-45082010RW1134
Zhang, Y., Li, H., Jin, S., Lu, Y., Peng, Y., Zhao, L., & Wang, X. (2022). Cannabidiol protects against Alzheimer's disease in C. elegans via ROS scavenging activity of its phenolic hydroxyl groups. European journal of pharmacology, 919, 174829. https://doi.org/10.1016/j.ejphar.2022.174829
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Maria Vitória Frota Magalhães; Ruymara Candal Nogueira ; Joana Baschung Bertazzon; Andressa Gonçalves Vicente; Marcos Gabriel Bastos Sereno; Carlos Vinícius Teixeira Palhares; Marina Rodrigues e Silva
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
